Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Computing & Software
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
The University of Bristol has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 3 distinct examiners and 3 distinct art units, indicating separate examination paths within the same technology area.
KEOGH, MATTHEW R is the busiest examiner with 1 pending matter. Portfolio oversight should preserve application-specific arguments while identifying any recurring biotechnology or pharmaceutical issues across the separate matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| §103 only | 1 (20%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KEOGH, MATTHEW R | 1 | 78.5% | +14.4% |
| LANE, THOMAS BERNARD | 1 | 75.0% | +11.9% |
| GAUGER, PAUL RANDALL | 1 | 59.3% | +8.3% |
| FRITCHMAN, REBECCA M | 1 | 45.6% | +35.4% |
| MATALKAH, FATIMAH KHALAF | 1 | 55.8% | +27.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18729464 | Anti-Leak System and Methods | LANE, THOMAS BERNARD | — |
| 18538777 | 4-SUBSTITUED CYTISINE ANALOGUES | GAUGER, PAUL RANDALL | — |
| 18247865 | MEANS AND METHODS TO DIAGNOSE GUT FLORA DYSBIOSIS AND INFLAMMATION | FRITCHMAN, REBECCA M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18011592 | VECTOR | MATALKAH, FATIMAH KHALAF | 5d overdue |
| 18784407 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACID TO PLANT CELLS | KEOGH, MATTHEW R | — |
| 18729464 | Anti-Leak System and Methods | LANE, THOMAS BERNARD | — |
| 18247865 | MEANS AND METHODS TO DIAGNOSE GUT FLORA DYSBIOSIS AND INFLAMMATION | FRITCHMAN, REBECCA M | — |
| Art Unit | Apps |
|---|---|
| 1663 | 1 |
| 2142 | 1 |
| 1629 | 1 |
| 1758 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18784407 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACID TO PLANT CELLS | KEOGH, MATTHEW R | 1663 | §112 | Non-Final OA | — | Pending | Jul 25, 2024 |
| 18729464 | Anti-Leak System and Methods | LANE, THOMAS BERNARD | 2142 | §102§103§112 | Non-Final OA | — | Pending | Jul 16, 2024 |
| 18538777 | 4-SUBSTITUED CYTISINE ANALOGUES | GAUGER, PAUL RANDALL | 1629 | §102§112Other | Final Rejection | — | Pending | Dec 13, 2023 |
| 18247865 | MEANS AND METHODS TO DIAGNOSE GUT FLORA DYSBIOSIS AND INFLAMMATION | FRITCHMAN, REBECCA M | 1758 | §101§103§112 | Non-Final OA | — | Pending | Apr 04, 2023 |
| 18011592 | VECTOR | MATALKAH, FATIMAH KHALAF | 1638 | §103 | Non-Final OA | 5d overdue | Pending | Dec 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialThe University of Bristol has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Matthew R Keogh has the most, with 1 of The University of Bristol's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
